Changes in lumbar spine QCT, DXA and TBS with denosumab, alendronate or placebo in postmenopausal women with low bone mass
Thierry Thomas(Lyon 1 Université), Cesar Libanati(Amgen (United States)), Celia J. F. Lin, Matthew Austin(Amgen (United States)), Angela M. Cheung(Westat (United States)), Ann E. Kearns(Mayo Clinic), Didier Hans(University of Lausanne), Elizabeth Shane(Columbia University Irving Medical Center), José Zanchetta(Universidad del Salvador)
Cited by 2
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Functional Disability 5 Years after Acute Respiratory Distress Syndrome
|New England Journal of Medicine|2011|2.8k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k